Latest Celosia Therapeutics News & Updates

See the latest news and media coverage for Celosia. We track all announcements, press releases, and industry mentions in real time, all in one place.

Celosia Therapeutics (Celosia)

Gene therapy company developing treatments for neurological diseases

celosiatx.com

Headquarters: Sydney, Australia
Founded year: 2022
Company type: Private company
Number of employees: 1–6
Industry: Pharmaceuticals

Last updated August 8

Latest news about Celosia Therapeutics (Celosia)

In short: Celosia dosed its first patient in a Phase 1b trial of ALS gene therapy CTx1000.

Company announcements

August 8 Celosia

Celosia appoints Dr Armen Asatryan as Chief Medical Officer.

He will lead clinical development for gene therapy programs targeting ALS and other rare diseases, strengthening the biotech's neuroscience pipeline.

May 4 Celosia

Celosia Therapeutics doses first patient in Phase 1 study

The study tests CTX 1000's safety and efficacy for ALS patients at Macquarie University Hospital. Professor Lars Ittner highlights this milestone after 17 years of development.

March 24 Celosia

Celosia Therapeutics doses first patient in Phase 1b KOANEWA trial

The trial evaluates CTx1000 gene therapy targeting TDP-43 in ALS patients at Macquarie University Hospital. CEO highlights milestone for ALS community.

February 18 Celosia

Celosia secures $16.75M for ALS gene therapy

The funding supports the development of pioneering gene therapies aimed at treating Amyotrophic Lateral Sclerosis and Frontotemporal Dementia patients.

Media coverage

March 23 Australian Associated Press

Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis

CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS . SYDNEY, March 24, 2026 /PRNewswire/ -- Celosia Therapeutics, an Australian biotech company...

February 17, 2025 The Australian

Macquarie University spin-out Celosia Therapeutics nabs $16.8m to take ALS treatment to trial

Celosia Therapeutics, a Macquarie University spin-out, has picked up the funds by way of Uniseed for its lead treatment - called CTX-1000 - which is...

Never miss news about Celosia

Track Celosia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Celosia competitors & trending companies

Browse news for competitors to Celosia and other trending companies.